Selective kinase type III inhibitors

By 17/12/2015 Uncategorized No Comments

Foldyne Research International succesfully designs highly selective kinase type III inhibitors
Strong demand in oncology products from research groups in early phase drug discovery directed the research programme of FRI into the exploration of allosteric pockets of kinase (sub)families. Kinases belong to the best anti-cancer targets but are hardly drugable due to selectivity issues resulting in adverse effects for currently available drugs. The indirect interactions involved in type III inhibition are quantified with our Single-atom Analyser and uses binding modes of distant and non-conserved residues in adjacent ligand-binding pockets.

Leave a Reply